Clinical Trial Results:
A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combination regimen of anthracycline and cyclophosphamide as pre-operative therapy in patients with high risk localized breast cancer
Summary
|
|
EudraCT number |
2006-006473-24 |
Trial protocol |
GB DE FR BE |
Global completion date |
03 Jul 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Apr 2016
|
First version publication date |
06 Apr 2016
|
Other versions |
|
Summary report(s) |
EFC10073 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.